AIM： The genes were divided into seven categories according to biological function; apoptosis-related, immune response-related, signal transduction-related, cell cyclerelated, cell growth-related, stress response-rel...AIM： The genes were divided into seven categories according to biological function; apoptosis-related, immune response-related, signal transduction-related, cell cyclerelated, cell growth-related, stress response-related and transcription-related genes. METHODS： We compared the gene expression profiles of SNU-C4 cells between amygdalin-treated （5 mg/mL, 24 h） and non-treated groups using cDNA microarray analysis. We selected genes downregulated in cDNA microarray and investigated mRNA levels of the genes by RT- PC R. RESULTS： Microarray showed that amygdalin downregulated especially genes belonging to cell cycle category： exonuclease 1 （EXO1）, ATP-binding cassette, sub-family F, member 2 （ABCF2）, MRE11 meiotic recombination 11 homolog A （MRE11A）, topoisomerase （DNA） Ⅰ （TOP1）, and FK506 binding protein 12-rapamycin-associated protein 1 （FRAP1）. RT-PCR analysis revealed that mRNA levels of these genes were also decreased by amygdalin treatment in SNU-C4 human colon cancer cells. CONCLUSION： These results suggest that amygdalin have an anticancer effect via downregulation of cell cycle-related genes in SNU-C4 human colon cancer cells, and might be used for therapeutic anticancer drug.展开更多
基金Supported by a grant of the Oriental Medicine R&D Project, Ministry of Health Welfare, Republic of Korea, No. 03-PJ9-PG3-21600-0014 and No. 0405-OMOO-0815-0001 Korea Institute of Oriental Medicine
文摘AIM： The genes were divided into seven categories according to biological function; apoptosis-related, immune response-related, signal transduction-related, cell cyclerelated, cell growth-related, stress response-related and transcription-related genes. METHODS： We compared the gene expression profiles of SNU-C4 cells between amygdalin-treated （5 mg/mL, 24 h） and non-treated groups using cDNA microarray analysis. We selected genes downregulated in cDNA microarray and investigated mRNA levels of the genes by RT- PC R. RESULTS： Microarray showed that amygdalin downregulated especially genes belonging to cell cycle category： exonuclease 1 （EXO1）, ATP-binding cassette, sub-family F, member 2 （ABCF2）, MRE11 meiotic recombination 11 homolog A （MRE11A）, topoisomerase （DNA） Ⅰ （TOP1）, and FK506 binding protein 12-rapamycin-associated protein 1 （FRAP1）. RT-PCR analysis revealed that mRNA levels of these genes were also decreased by amygdalin treatment in SNU-C4 human colon cancer cells. CONCLUSION： These results suggest that amygdalin have an anticancer effect via downregulation of cell cycle-related genes in SNU-C4 human colon cancer cells, and might be used for therapeutic anticancer drug.
